Improving HIV testing and PrEP for transgender women through mHealth

通过移动医疗改善跨性别女性的艾滋病毒检测和 PrEP

基本信息

  • 批准号:
    10398983
  • 负责人:
  • 金额:
    $ 19.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-28 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Abstract Despite decades of evidence-based interventions, including the 90/90/90 strategy, the HIV epidemic in Malaysia remains volatile. With over 100,000 cumulative HIV cases, Malaysia's rapidly expanding HIV epidemic is the fifth largest in the Asia-Pacific region and is concentrated within the most-at-risk populations. Originally driven by people who inject drugs, the majority of new infections today (>90%) are attributed to sexual transmission, many of which occur among transgender women (TGW). TGW are disproportionately impacted by HIV worldwide, with an estimated global prevalence of 19%. In Malaysia, an estimated 12.4% of TGW are living with HIV. TGW experience multi-level vulnerabilities to HIV, including discrimination in employment and economic opportunities, steering many TGW into high-risk occupations, such as sex work. High levels of stigma and discrimination against TGW by healthcare providers can foster a hostile environment toward TGW, complicating efforts to scale-up of HIV testing and prevention services among trans women, including pre-exposure prophylaxis (PrEP). Modeling studies suggest increased HIV testing and uptake of PrEP is the most impactful and cost-effective strategy for reducing new infections. Despite this, only 37% of TGW in Malaysia have ever been HIV tested. Similarly, while PrEP is recommended in Malaysia's National Strategic Plan to End AIDS (2016-2030), only 1 in 5 TGW has ever heard of PrEP. However, after learning about PrEP, more than 80% of TGW in Malaysia say they would take it. To scale-up of HIV testing and PrEP among TGW, innovative strategies are needed to rapidly overcome the complex barriers preventing uptake. In settings where anti-trans stigma is pervasive, such as Malaysia, mHealth may provide an empowering alternative approach to service delivery for TGW. An effective platform for reaching vulnerable and hidden populations, mHealth can overcome barriers associated with traditional clinic-based care by designing customized models of care tailored to the needs of vulnerable populations. Through confidential screening, rapid referrals to trans-friendly providers, and tools that facilitate access to gender-affirming health care needs, mHealth is a promising platform that can be leveraged for intervening around HIV prevention. Thus, we propose to develop and test a new clinic-affiliated app, called MyLink2care, to deliver an integrated HIV prevention intervention for TGW in Malaysia. Specifically, we propose to: 1) adapt, expand, and refine an existing mobile application by conducting formative research with TGW and clinical stakeholders to develop a prototype of the MyLink2Care app to undergo usability testing, followed by development of the beta version of the app; 2) conduct “beta testing” of the MyLink2Care app to assess its usability and acceptability; and 3) assess preliminary feasibility and acceptability of the MyLink2care app within a pilot, randomized-controlled trial, compared with treatment-as-usual for engagement in HIV prevention.
摘要 尽管数十年来采取了循证干预措施,包括90/90/90战略,但#年艾滋病毒流行。 马来西亚仍然不稳定。马来西亚艾滋病毒累计病例超过10万例,快速增长的艾滋病毒 疫情是亚太地区第五大疫情,集中在高危人群中。 最初是由注射毒品的人推动的,如今大多数新感染(>90%)归因于 性传播,其中许多发生在变性人妇女(TGW)中。TGW不成比例地 在全球范围内受艾滋病毒影响,全球流行率估计为19%。在马来西亚,估计有12.4%的 TGW感染了艾滋病毒。TGW对艾滋病毒有多层次的脆弱性,包括在 就业和经济机会,引导许多TGW从事高风险的职业,例如性工作。 医疗保健提供者对TGW的高度耻辱和歧视可能会滋生一种敌对的环境 TGW,使在变性妇女中扩大艾滋病毒检测和预防服务的努力复杂化, 包括暴露前预防(PrEP)。模拟研究表明,艾滋病毒检测和对 PREP是减少新感染的最有效和最具成本效益的策略。尽管如此,只有37%的人 马来西亚的TGW曾接受过艾滋病毒检测。同样,虽然马来西亚国家医疗保险公司推荐使用PrEP 在《结束艾滋病战略规划(2016-2030年)》中,只有五分之一的TGW听说过PrEP。然而,在得知后, 关于PrEP,马来西亚超过80%的TGW表示他们会接受。扩大艾滋病毒检测和预防接种计划 在TGW中,需要采取创新战略,迅速克服阻碍吸收的复杂障碍。在……里面 在反跨性别歧视普遍存在的环境中,如马来西亚,mHealth可能会提供一种赋权 TGW提供服务的替代方法。一个有效的平台,帮助脆弱和隐蔽的人 人口,移动健康可以克服与传统的基于诊所的护理相关的障碍,通过设计 根据弱势群体的需要定制护理模式。通过保密筛选, 快速转介给跨性别友好的提供者,以及便利获得性别平等的医疗保健需求的工具, 移动健康是一个很有希望的平台,可以用来干预艾滋病毒预防。因此,我们 建议开发和测试一款名为MyLink2care的诊所附属新应用程序,以提供集成的艾滋病毒 马来西亚对TGW的预防干预。具体地说,我们建议:1)调整、扩展和优化 通过与TGW和临床利益相关者进行形成性研究来开发现有的移动应用程序 MyLink2Care应用程序的原型将进行可用性测试,随后将开发 该应用程序;2)对MyLink2Care应用程序进行“测试版测试”,以评估其可用性和可接受性;以及3) 在随机对照的试点试验中评估MyLink2care应用程序的初步可行性和可接受性 试验,与参与艾滋病毒预防的照常治疗相比。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Roman Shrestha其他文献

Roman Shrestha的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Roman Shrestha', 18)}}的其他基金

Integrated online-to-offline (O2O) model of care for HIV prevention and treatment among men who have sex with men
男男性行为者艾滋病预防和治疗的线上线下(O2O)一体化护理模式
  • 批准号:
    10548402
  • 财政年份:
    2022
  • 资助金额:
    $ 19.14万
  • 项目类别:
Integrated online-to-offline (O2O) model of care for HIV prevention and treatment among men who have sex with men
男男性行为者艾滋病预防和治疗的线上线下(O2O)一体化护理模式
  • 批准号:
    10665762
  • 财政年份:
    2022
  • 资助金额:
    $ 19.14万
  • 项目类别:
An online HIV self-testing intervention with online-to-offline linkage to care for transgender women
在线艾滋病自检干预,线上线下联动,关爱跨性别女性
  • 批准号:
    10772677
  • 财政年份:
    2022
  • 资助金额:
    $ 19.14万
  • 项目类别:
Improving HIV testing and PrEP for transgender women through mHealth
通过移动医疗改善跨性别女性的艾滋病毒检测和 PrEP
  • 批准号:
    10258220
  • 财政年份:
    2021
  • 资助金额:
    $ 19.14万
  • 项目类别:
Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSM
开发和测试移动应用程序以加强马来西亚男男性接触者的艾滋病毒预防级联
  • 批准号:
    10367278
  • 财政年份:
    2021
  • 资助金额:
    $ 19.14万
  • 项目类别:
Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSM
开发和测试移动应用程序以加强马来西亚男男性接触者的艾滋病毒预防级联
  • 批准号:
    10261542
  • 财政年份:
    2021
  • 资助金额:
    $ 19.14万
  • 项目类别:
Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSM
开发和测试移动应用程序以加强马来西亚男男性接触者的艾滋病毒预防级联
  • 批准号:
    10673162
  • 财政年份:
    2020
  • 资助金额:
    $ 19.14万
  • 项目类别:
Integrated rapid access to HIV prevention program for people who inject drugs (iRaPID)
注射吸毒者综合快速获得艾滋病毒预防计划 (iRaPID)
  • 批准号:
    10082915
  • 财政年份:
    2020
  • 资助金额:
    $ 19.14万
  • 项目类别:
Training in MHealth Prevention with MSM
MSM 的 MHealth 预防培训
  • 批准号:
    10673645
  • 财政年份:
    2020
  • 资助金额:
    $ 19.14万
  • 项目类别:
Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs (RAPID)
注射吸毒者综合快速艾滋病毒预防计划 (RAPID)
  • 批准号:
    10224917
  • 财政年份:
    2020
  • 资助金额:
    $ 19.14万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 19.14万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 19.14万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 19.14万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 19.14万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 19.14万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 19.14万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 19.14万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 19.14万
  • 项目类别:
Studies on cofactors for development of acquired immunodeficiency syndrome in feline immunodeficiency virus infection.
猫免疫缺陷病毒感染后获得性免疫缺陷综合征发生的辅助因子研究。
  • 批准号:
    03660315
  • 财政年份:
    1991
  • 资助金额:
    $ 19.14万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 19.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了